Group 1 - The major shareholder, Hunan Zhongqi Dongjian Private Equity Investment Partnership, held 10,457,516 shares, accounting for 5.16% of the total share capital before the reduction plan [1] - The reduction plan was disclosed on March 7, 2025, with the intention to reduce shares due to funding needs, allowing for a maximum reduction of 1% within three months [1] - As of June 16, 2025, the shareholder had completed the reduction of 2,026,780 shares through centralized bidding, resulting in a current holding of 8,430,736 shares, or 4.16% [2][3] Group 2 - The reduction price range was between 9.85 and 15.54 yuan per share, with a total reduction amount of 22,068,414.24 yuan [2] - The actual reduction was consistent with the previously disclosed plan, confirming that the minimum reduction quantity was achieved [3]

Core Points - The annual general meeting of Shanghai Cathay Biotech Co., Ltd. is scheduled for June 27, 2025, at 14:00, combining on-site and online voting methods [3][4] - The company reported a significant increase in revenue and net profit for 2024, with total revenue reaching CNY 2,957.91 million, a 39.91% increase year-on-year, and net profit attributable to shareholders amounting to CNY 488.96 million, a 33.41% increase [16][32] - The company plans to distribute a cash dividend of CNY 4.00 per 10 shares, totaling CNY 287.58 million, based on the audited net profit for 2024 [8][9] Meeting Procedures - Attendees must register and confirm their attendance before the meeting starts, and they are required to present their shareholder certificates to enter the venue [2][3] - The meeting will include the election of monitors and counters, the presentation of the independent directors' report, and the discussion of various proposals [4][6][11] Financial Performance - The company achieved a net profit of CNY 488.96 million in 2024, with a significant increase in net profit excluding non-recurring gains and losses, which rose by 51.60% to CNY 464.73 million [16][32] - The total assets of the company reached CNY 19.02 billion, reflecting a stable financial position [32] Strategic Developments - The company has successfully introduced CNY 5.915 billion in funding through a directed issuance of shares to enhance its business development [18] - A strategic cooperation agreement was signed with Hefei Municipal Government and China Merchants Innovation Technology Group to establish a synthetic biological materials industry cluster [18][28] Governance and Compliance - The board of directors and the supervisory board have actively fulfilled their responsibilities, ensuring compliance with relevant laws and regulations [19][25] - The company has maintained a high standard of information disclosure, achieving an A-level rating for its disclosure practices in the Shanghai Stock Exchange [23][26]

作 者丨尹华禄 编 辑丨刘巷 6月16日盘后，奥精医疗（688613.SH）董事会沉痛公告，公司收到公司创始人、实际控制人 之一崔福斋家属通知，崔福斋于近日因病不幸逝世，享年80岁。 据奥精医疗介绍，崔福斋为公司的发展倾注了毕生心血，带领公司逐步发展壮大成为生物材 料行业领先企业、科创板上市公司，作出了巨大贡献。 奥精医疗官网显示，该公司是是一家致力于组织再生修复植入医疗器械的研发、生产和销售 的技术企业。2011年率先在国际上研制出成分和结构均与天然人体骨组织高度相似的矿化胶 原仿生骨材料，并实现了产品的临床转化和产业化。使得我国在这一医疗器械领域处于国际 地位。目前矿化胶原仿生骨系列产品广泛应用于骨科、口腔科、神经外科等领域的骨缺损修 复，现已在临床使用超百万例。 截至公告披露之日，崔福斋直接持有奥精医疗633.48万股，占总股本的4.62%，通过北京银河 九天信息咨询中心（有限合伙）间接持有35.41万股，占总股本的0.26%。崔福斋所持有的公 司股份将按法律法规办理继承手续，奥精医疗将根据后续事项进展情况及时履行信息披露义 务。 "崔福斋在公司担任首席科学家职务，不属于公司管理层，不会引起公司管理层变 ...

Core Viewpoint - The passing of Cui Fuzhai, the founder and actual controller of AoJing Medical, is a significant event for the company, but it is stated that his death will not impact the company's operations or management stability [1][4]. Group 1: Company Background - AoJing Medical (688613.SH) is a leading enterprise in the biomaterials industry and a listed company on the Sci-Tech Innovation Board, founded by Cui Fuzhai in 2004 [1][5]. - The company specializes in the research, development, production, and sales of implantable medical devices aimed at tissue regeneration and repair [5]. - AoJing Medical developed the mineralized collagen biomimetic bone material in 2011, which closely resembles natural human bone tissue, achieving clinical transformation and industrialization [5]. Group 2: Contributions of Cui Fuzhai - Cui Fuzhai held multiple academic and professional roles, including professor and doctoral supervisor at Tsinghua University, and was recognized as a fellow by several prestigious engineering societies [3][4]. - His research focused on biomaterials science and engineering, particularly in the areas of natural mineralization mechanisms of bones and teeth, and the development of biomimetic materials [4]. - Under his leadership, AoJing Medical has launched a series of patented products, including mineralized collagen artificial bone powder and membranes, which have been widely used in clinical settings [4][5]. Group 3: Shareholding and Succession - As of the announcement date, Cui Fuzhai directly held 6.3348 million shares of AoJing Medical, accounting for 4.62% of the total share capital, and indirectly held 354,100 shares through a partnership [1]. - The shares held by Cui Fuzhai will be subject to inheritance procedures according to legal regulations, and the company will fulfill its information disclosure obligations as necessary [1].

证券代码：688363 证券简称：华熙生物 华熙生物科技股份有限公司 2024 年年度股东大会会议资料 华熙生物科技股份有限公司 2024 年年度股东大会会议资料 华熙生物科技股份有限公司 2024 年年度股东大会会议资料 华熙生物科技股份有限公司 为保障华熙生物科技股份有限公司（以下简称"公司"）全体股东的合法权 益，维护股东大会的正常秩序，保证股东大会的议事效率，确保本次股东大会如 期、顺利召开，根据《中华人民共和国公司法》《华熙生物科技股份有限公司章 程》《华熙生物科技股份有限公司股东大会议事规则》等相关规定，特制定公司 一、为保证股东大会的有序进行，切实维护股东的合法权益，现场出席会议 的股东及股东代理人需进行会议登记，以核实股东资格。会议开始后，现场会议 登记将终止，会议主持人将宣布现场出席会议的股东和代理人人数及所持有表决 权的股份总数。为了顺利参加股东大会，建议股东提前半小时到达会议现场，并 按规定出示会议登记所需资料办理会议登记。 二、为保证股东大会的正常秩序，除出席会议的股东及股东代理人、公司董 事、监事、高级管理人员、公司聘请的律师及董事会邀请的其他人员外，公司有 权拒绝其他无关人员进入会 ...

证券代码：600165 股票简称：ST 宁科 公告编号：临 2025-068 宁夏中科生物科技股份有限公司 关于重整及预重整事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容及风险提示： ● 截至本公告披露日，宁夏中科生物科技股份有限公司（以下简称：公司 或宁科生物）除已披露的被申请重整及预重整、子公司宁夏中科生物新材料有 限公司（以下简称：中科新材）被法院裁定进行重整的事项外，未发生该事项 相关进展。 ● 中科新材进入重整程序，重整能否成功存在不确定性，如法院最终裁定 中科新材重整不成功，将存在被法院宣告破产的风险，公司将可能失去对中科 新材的控制权，存在失去对子公司的持股的风险，届时公司将无法再将中科新 材纳入合并报表，对公司资产、本期及期后利润产生一定的影响。但目前公司 仍为中科新材控股股东，对其后续重整过程及重整计划草案表决拥有表决权及 一定的决策权。此外，中科新材重整是基于公司及子公司整体协同重整、按统 一方案同时完成重整的整体计划及整体安排的基础上进行，并非孤立事件。如 按公司原定计划，公司能 ...

中信建投证券股份有限公司 关于浙江海正生物材料股份有限公司 差异化分红事项的核查意见 中信建投证券股份有限公司（以下简称"保荐机构"、"中信建投证券"）作为 浙江海正生物材料股份有限公司（以下简称"公司"或"海正生材"）首次公开发行 股票并在科创板上市及进行持续督导的保荐机构，根据《上海证券交易所科创板 股票上市规则》《证券发行上市保荐业务管理办法》《上海证券交易所上市公司 自律监管指引第7号——回购股份》等有关法律法规和规范性文件的要求，对海 正生材2024年度利润分配涉及的差异化分红事项进行了核查，并发表核查意见如 下： 一、本次实施差异化权益分派的原因 集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金通过集中 竞价交易方式回购公司股份。回购股份用于公司股权激励或员工持股计划，回购 价格不超过人民币12.00元/股（含），回购资金总额不低于人民币2,000万元（含）， 不超过人民币3,000万元（含），具体回购股份的数量以回购期满时实际回购的 股份数量为准。回购期限自董事会审议通过本次回购方案之日起12个月内。 根据《上海证券交易所上市公司自律监管指引第7号——回购股份》第二十 二条规定"上 ...

证券代码：688203 证券简称：海正生材 公告编号：2025-30 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 是否涉及差异化分红送转：是 ? 每股分配比例 每股现金红利0.06005元 ? 相关日期 股权登记日 除权（息）日 现金红利发放日 公司于 2025 年 5 月 8 日召开了 2024 年年度股东会，会议审议通过了《2024 年度利润分配预案》，具体分配方案如下： 公司 2024 年度拟以实施权益分派股权登记日登记的总股本扣除公司回购专用 证券账户股份数后的股本为基数分配利润，拟向全体股东每 10 股派发现金 0.60 元（含税）。截至公司 2024 年度利润分配方案披露日，公司总股本 202,678,068 股扣除公司回购专用证券账户股份 1,256,874 股后的股本基数为 201,421,194 股， 以此计算合计拟派发现金红利 12,085,271.64 元（含税）。本年度以现金为对价， 采用集中竞价方式已实施的股份回购金额 8,998,849.64 元（不含印花税、交易佣 金等交 ...

Core Insights - Shanghai Blue Crystal Microbial Technology Co., Ltd. has achieved significant breakthroughs in the field of polyhydroxyalkanoates (PHA) biomanufacturing, addressing global plastic pollution and carbon neutrality challenges [1][4] - The company has set a global record with a production yield of 300 grams per liter, a 100% carbon source conversion rate, and a 64% reduction in carbon footprint [1][4] Group 1: PHA Production and Characteristics - PHA is a natural biodegradable polymer synthesized by microorganisms, with a degradation efficiency 100 times that of traditional plastics [2] - The historical challenge of scaling PHA production has been addressed by Blue Crystal's innovative use of oil-based raw materials, reducing production costs to $590 per ton [2][3] - The company has achieved a production concentration of 300 grams per liter, surpassing previous industrial benchmarks [2][4] Group 2: Technological Innovations - The Biohybrid technology system developed by the research team has led to two major innovations, enhancing production efficiency and carbon source utilization [4] - The 1.0 version activated the Calvin cycle in industrial strains, increasing fermentation tank yields by 20% [4] - The 2.0 version optimized the oil utilization capacity of strains, achieving a carbon source conversion rate exceeding 100% [4] Group 3: Environmental Impact - The adoption of Biohybrid 2.0 technology has reduced the carbon footprint of PHA to 2.01 kilograms of CO2 equivalent per kilogram, marking a 64% decrease compared to traditional petrochemical plastics [4] - PHA can degrade in approximately two weeks to six months under natural conditions, significantly faster than conventional plastics [5]

Core Insights - Chengdu East New Area is leveraging scene innovation to enhance the transformation of results, promoting deep integration of technological and industrial innovation [1][2] - The "front store, back factory" model implemented by Chengdu Anke Xing Technology Co., Ltd. in Chengdu Future Medical City signifies a new development model that reshapes the industrial ecosystem and stimulates new consumption potential [1] Group 1: Scene Innovation and Industrial Ecosystem - The unveiling of the "front store, back factory" innovation scene marks a significant step in reshaping the industrial ecosystem within the park, aiming to cultivate new productive forces and stimulate consumption [1] - The model integrates research, production, and consumer experience, allowing for direct consumer access to newly developed technological skincare products, effectively reducing the distance from laboratory to shelf [1] Group 2: Enterprise Support System - Chengdu Future Medical City has established a robust "We Hello" enterprise service system, focusing on innovation-driven and service-enabled approaches, which includes a comprehensive "1+2+3+N" service framework [2] - The service system provides a three-tier response mechanism to meet the lifecycle needs of enterprises, ensuring precise alignment between enterprise services and industrial demands [2] - Financial products like the "Future Medical Sci-Tech Loan" support startups by offering no-collateral, no-flow loans, facilitating technological innovation and industrial upgrades [2] Group 3: Future Development and Economic Growth - Chengdu Future Medical City plans to create more diverse innovation scenes and explore new pathways for technology transformation, aiming to inject new momentum into regional economic high-quality development [2]